National Cancer Institute: SEER Cancer Stat Facts: Female Breast Cancer.
Bethesda, Md: National Cancer Institute.Available online.
Last accessed April 9, 2025.
Seidman AD, Bordeleau L, Fehrenbacher L, et al.: National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
J Clin Oncol 36 (32): 3259-3268, 2018.[PUBMED Abstract] Rugo HS, Diéras V, Gelmon KA, et al.: Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Ann Oncol 29 (4): 888-894, 2018.[PUBMED Abstract] Rugo HS, Finn RS, Diéras V, et al.: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.